ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

ClinicalTrials.gov ID: NCT00143117

Public ClinicalTrials.gov record NCT00143117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 12:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation

Study identification

NCT ID
NCT00143117
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
460 participants

Conditions and interventions

Conditions

Interventions

  • UK-390,957 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2004
Primary completion
May 31, 2005
Completion
May 31, 2005
Last update posted
Nov 6, 2012

2004 – 2005

United States locations

U.S. sites
51
U.S. states
23
U.S. cities
51
Facility City State ZIP Site status
Pfizer Investigational Site Tucson Arizona
Pfizer Investigational Site Anaheim California
Pfizer Investigational Site Atherton California
Pfizer Investigational Site Beverly Hills California
Pfizer Investigational Site Laguna Woods California
Pfizer Investigational Site Newport Beach California
Pfizer Investigational Site Redwood City California
Pfizer Investigational Site San Diego California
Pfizer Investigational Site Tarzana California
Pfizer Investigational Site Walnut Creek California
Pfizer Investigational Site Aurora Colorado
Pfizer Investigational Site Waterbury Connecticut
Pfizer Investigational Site Aventura Florida
Pfizer Investigational Site New Port Richey Florida
Pfizer Investigational Site Pembroke Pines Florida
Pfizer Investigational Site Evansville Indiana
Pfizer Investigational Site Fort Wayne Indiana
Pfizer Investigational Site Indianapolis Indiana
Pfizer Investigational Site Michigan City Indiana
Pfizer Investigational Site Lexington Kentucky
Pfizer Investigational Site Madisonville Kentucky
Pfizer Investigational Site Metairie Louisiana
Pfizer Investigational Site Milford Massachusetts
Pfizer Investigational Site Saint Clair Shores Michigan
Pfizer Investigational Site Minneapolis Minnesota
Pfizer Investigational Site Southhaven Mississippi
Pfizer Investigational Site Kansas City Missouri
Pfizer Investigational Site Reno Nevada
Pfizer Investigational Site Edison New Jersey
Pfizer Investigational Site New Brunswick New Jersey
Pfizer Investigational Site Voorhees Township New Jersey
Pfizer Investigational Site Albany New York
Pfizer Investigational Site Endwell New York
Pfizer Investigational Site New York New York
Pfizer Investigational Site West Seneca New York
Pfizer Investigational Site Williamsville New York
Pfizer Investigational Site Charlotte North Carolina
Pfizer Investigational Site Durham North Carolina
Pfizer Investigational Site Beachwood Ohio
Pfizer Investigational Site Tulsa Oklahoma
Pfizer Investigational Site Germantown Tennessee
Pfizer Investigational Site Knoxville Tennessee
Pfizer Investigational Site Memphis Tennessee
Pfizer Investigational Site Milan Tennessee
Pfizer Investigational Site Dallas Texas
Pfizer Investigational Site Fort Worth Texas
Pfizer Investigational Site Houston Texas
Pfizer Investigational Site Plano Texas
Pfizer Investigational Site San Antonio Texas
Pfizer Investigational Site Tacoma Washington
Pfizer Investigational Site Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00143117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2012 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00143117 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →